AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 191 min read$TEM

LEFKOFSKY ERIC P sold $16.1M of TEM (indirect holdings)

LEFKOFSKY ERIC P (CEO and Chairman) sold 200,000 indirectly-held shares of Tempus AI, Inc. (TEM) at an average of $80.57 ($80.52–$81.09, $16.11M total) across 6 trades on 2026-09-17 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · LEFKOFSKY ERIC P
Published Sep 19, 2026, 1:15 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 19, 2026, 1:35 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$TEM
Bearish
medium confidence
Mentioned
$TEM
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TEMBearishLow
01

Why it matters

The disclosed sale may trigger short‑term selling pressure but likely has limited long‑term effect.

02

Market read

Insider sell of $16M is a notable event for traders monitoring Tempus AI and the broader health‑tech sector.

03

What to watch

The 10b5‑1 plan may have been set months ago; the sale does not reflect current sentiment.

Relevance 6/10Novelty 7/10Timing: post‑market filing on Sep 18 2026

Background

Form 4 filings disclose insider transactions; a 10b5‑1 plan allows pre‑scheduled sales.

Company-level read

Ticker impact

$TEMBearishMedium confidence
Context

CEO Eric Lefkofsky sold 200,000 shares for $16.1M via a 10b5-1 plan, reducing his stake to 809,631 shares.

Expected impact

Modest short‑term decline as the market digests the $16M sell‑off.

Evidence & confidence

A $16M sale by the CEO is sizable for a mid‑cap biotech, indicating possible concerns about valuation or upcoming developments.

Market effects

Sector

Healthcare AI sector may see heightened scrutiny after a top executive's sizable sell‑off.

Regional

Limited to U.S. investors; no broader regional effect.

Global

Minimal global impact beyond Tempus AI shareholders.

Counterpoint

What could challenge this read

The sale could be a routine liquidity event under a pre‑arranged plan, not a signal of trouble.

Key entities

  • Company
    Tempus AI, Inc.

    AI‑driven healthcare data platform listed on Nasdaq under ticker TEM.

  • Executive
    Eric Lefkofsky

    CEO and Chairman of Tempus AI, 10% owner.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

TEM insider trading history →

Related articles

OCT 26
$TEMMed

What Happens To Tempus AI Stock If Its Cash Burn Continues?

Tempus AI (TEM) expects positive free cash flow by year-end but had a $273M cash burn over the past year. With $816M in cash, the company's reserves could last about three years at current burn rates. Revenue grew 20% and 36% in diagnostics and data businesses, respectively. Management raised 2026 revenue guidance to $1.595B-$1.605B and issued $460M in convertible notes. The company plans to acquire Personalis, potentially using debt to fund the deal.

finance.yahoo.com2 min
OCT 26
$BMYMed

Pathos AI Announces Strategic Collaborations with Bristol Myers Squibb and Tempus AI to Advance AI-Driven Drug Development Beginning with Alzheimer’s Disease and Other Neurological Conditions

Pathos AI has partnered with Bristol Myers Squibb (BMY) and Tempus (TEM) to advance AI-driven drug development for Alzheimer’s and other neurological conditions. Tempus will create a dataset from hundreds of thousands of patients, which Pathos will license for $55 million over five years. BMY leads Pathos's Series E financing and gains access to Pathos's AI platform, Pathos Foundry, for its R&D portfolio, with exclusive rights in neuroscience for three years.

biospace.com3 min
OCT 24
$BMYMed

Tempus Sets $55 Million Ceiling for Pathos Neurology Data Contract

Tempus AI signed a five-year neurology data deal with Pathos AI, potentially worth $55 million. Tempus will deliver up to 500,000 records, with Pathos paying $100 per record. Bristol Myers Squibb gains nonexclusive Foundry access and three-year exclusive rights for neuroscience development. Tempus also has a $137.5 million oncology deal with BMS, totaling $192.5 million if both deals reach full value.

econotimes.com2 min
OCT 23
$TEMMed

Tempus AI Gains 6% as Bristol Myers Squibb Licenses Oncology Data

Tempus AI shares rose 6% after Bristol Myers Squibb agreed to a multi-year deal to license its oncology data through 2031. Tempus's data and AI platform will support BMS's drug discovery and development. Data licensing is Tempus's most profitable segment, with 36% revenue growth in Q2. The financial terms of the deal were not disclosed.

finance.yahoo.com2 min